Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2019)
22 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 27, 2019
Slide 1: AGM Presentation: Cynata Therapeutics Limited
For personal use only A Next Generation Stem Cell Therapeutics Company AGM Presentation: Cynata Therapeutics Limited 27 November 2019
Slide 2: Dr Ross Macdonald, MD & CEO
For personal use only Dr Ross Macdonald MD & CEO
Slide 3: Important Information
Important Information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 4: Our focus
For personal use only Our focus Using our proprietary CymerusTM platform technology to develop commercially scalable cellular therapeutic products to treat serious chronic disorders www.cynata.com 4
Slide 5: Agenda
Agenda For personal use only 1 2019 Highlights: driving clinical and commercial success 2 FUJIFILM: license for GvHD 3 Current strategic focus: attractive licensing business model 4 Cymerus: a scalable, globally applicable technology 5 Market: attractive regenerative medicine industry 6 Outlook: thr
Slide 6: 2019 Highlights: Driving Clinical and Commercial Success
2019 Highlights: Driving Clinical and Commercial Success For personal use only FUJIFILM license Progressing to three Advanced pre-clinical agreement Phase II trials program FUJIFILM endorsement validates Expected to commence in CY20 Therapeutic potential in Cynata’s Cymerus platform for GvHD,
Slide 7: Multiple options to create shareholder value
Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value For personal use only Multiple options to create shareholder value case study Build value in platform independently Exclusive global licence in GvHD Multiple cash flow
Slide 8: Value inflection point following clear data and first commercial transaction
Value inflection point following clear data and first commercial transaction, with Cynata’s focus on further license agreements For personal use only Successful clinical study data Cynata’s current focus Demonstrating efficacy of our Commercialise technology via technology platform further licence a
Slide 9: Cymerus platform has potential applications across a wide range of diseases
Cynata's Cymerus platform has potential applications across a wide range of diseases For personal use only Cynata’s current focus: commercialise technology via further licence agreements Crohn’s Graft vs Host Disease Disease Others (GvHD) Fistula Coronary Artery Disease (CAD) Potential future target
Slide 10: COO Dr Kilian Kelly
For personal use only COO Dr Kilian Kelly
Slide 11: Patented Cymerus platform enables production of iPSC-derived cellular therapeutics
Our patented Cymerus platform enables the production of iPSC-derived cellular therapeutics from a single adult donor Conventional MSC processes For personal use only MSCs change when excessively Extensive MSC Cells from donors MSC isolation culture expansion expanded: loss of potency, senescence, de
Slide 12: Cynata's MSCs are high quality and commercially scalable
Cynata‘s MSCs are high quality and commercially scalable For personal use only Key advantages of the Cymerus process Consistent product quality – single donor overcomes regulatory concerns CONSISTENCY Bypasses complex and invasive surgeries with a scalable and cost-effective process & SCALABILIT
Slide 13: Clinical use of MSCs continues to grow
Clinical use of MSCs continues to grow For personal use only Over 1,000 clinical trials with MSCs Growing body of evidence for the role have been initiated1 of MSCs in repair and regeneration Number of MSC clinical trials (cumulative) 1,000 Regenerate diseased and 800 damaged tissue 600 Modulate t
Slide 14: Multiple MSC-based therapies are now on the market
Multiple MSC-based therapies are now on the market For personal use only Approved treatments: Cupistem® (Anterogen) for Crohn’s fistula Graft vs. Host Disease (GvHD) ® (Anterogen) for connective tissue disorders Queencell NeuroNata-R® (Corestem) for motor neurone disease TEMCELL® (JCR Pharma) for ac
Slide 15: Further MSC marketing approvals expected in near future
Further MSC marketing approvals expected in near future For personal use only ~30 Phase 3 trials with MSC-based Cynata is well placed in the therapies currently active MSC-based therapy market Graft vs. Host Disease (GvHD) Many ongoing Phase 3 trials involve Indications include: very common conditio
Slide 16: Cynata is targeting significant market opportunities
Cynata is targeting significant market opportunities For personal use only TARGET AREA TRIAL PHASE MARKET OPPORTUNITY Graft vs. Host Entering Clinical US $0.3bn1 Disease (GvHD) Phase II Critical limb Entering Clinical Phase II US $1.4bn2 ischemia (CLI) Entering Clinical Osteoarthritis (OA) Phase II
Slide 17: Critical limb ischemia (CLI)
Critical limb ischemia (CLI) For personal use only CLI is an advanced stage of PAD2 caused by a narrowing of the arteries in the limbs1 • PAD affects 3-10% of people aged <70 and 15-20% of people >701 • Risk factors include diabetes,, atherosclerosis, smoking, high blood pressure, high cholesterol •
Slide 18: Substantial body of evidence supporting use of MSCs to treat CLI/PAD
Substantial body of evidence supporting use of MSCs to treat CLI/PAD For personal use only Mice dosed with Cymerus MSCs experienced significantly improved outcomes when compared with control group DAY TREATED CONTROL Loss of leg Animals treated with Cymerus MSCs experienced improved blood flow (p<0.
Slide 19: Critical Limb Ischemia: Overview of Cynata-led Phase II program
Critical Limb Ischemia | Overview of Cynata-led Phase II program For personal use only 230,000 ~US$1.4B1 Addressable events per year Forecast annual global market sales Estimated market size Critical Limb MSC therapy for effective treatment of CLI patients who are ineligible for Ischemia (CLI) rev
Slide 20: Osteoarthritis: New Phase II program funded by NHMRC
Osteoarthritis | New Phase II program funded by National Health and Medical Research Council For personal use only 30,000,000 ~US$11.6B1 People in the USA affected by Forecast global market opportunity by Estimated market size osteoarthritis 2025 Assess the effect of Cymerus MSCs on clinical outco
Slide 21: Large pipeline of indications with upcoming catalysts
Cynata has a large pipeline of indications with upcoming catalysts Today For personal use only H1 CY2019 H2 CY2019 H1 CY2020 Upcoming catalysts / status Phase II trial expected to commence Graft vs in CY2020; FUJIFILM to bear Phase II trial planning Host Disease license responsibility for further de
Slide 22: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 62 Lygon Street ross.macdonald@cynata.com Carlton Victoria 3053 www.cynata.com Australia
Cynata Therapeutics — Shareholder Meeting (November 2019) on 6ix